Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stake Cut by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.1% in the 4th quarter, Holdings Channel reports. The firm owned 15,312 shares of the medical equipment provider’s stock after selling 334 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Zimmer Biomet were worth $1,620,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Blue Trust Inc. grew its stake in Zimmer Biomet by 165.3% during the 3rd quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock worth $187,000 after buying an additional 1,071 shares during the last quarter. International Assets Investment Management LLC grew its position in shares of Zimmer Biomet by 19,988.0% during the third quarter. International Assets Investment Management LLC now owns 107,471 shares of the medical equipment provider’s stock worth $11,601,000 after acquiring an additional 106,936 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Zimmer Biomet by 15.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 28,145 shares of the medical equipment provider’s stock worth $3,038,000 after acquiring an additional 3,859 shares during the period. Tectonic Advisors LLC lifted its position in Zimmer Biomet by 20.8% in the 3rd quarter. Tectonic Advisors LLC now owns 3,647 shares of the medical equipment provider’s stock valued at $394,000 after purchasing an additional 629 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Zimmer Biomet by 26.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,511 shares of the medical equipment provider’s stock valued at $1,895,000 after purchasing an additional 3,633 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 1.2 %

Shares of NYSE:ZBH opened at $104.89 on Friday. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The company has a market cap of $20.88 billion, a PE ratio of 23.57, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The firm has a 50 day simple moving average of $105.86 and a 200 day simple moving average of $107.45.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the firm earned $2.20 earnings per share. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were issued a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s dividend payout ratio is 21.57%.

Analyst Upgrades and Downgrades

ZBH has been the subject of several analyst reports. Truist Financial reiterated a “hold” rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Raymond James reduced their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Wells Fargo & Company raised their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Barclays reduced their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Finally, JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.